InflaRx N.V. (NASDAQ:IFRX) Short Interest Up 28.0% in May

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) was the recipient of a large growth in short interest in May. As of May 31st, there was short interest totalling 1,270,000 shares, a growth of 28.0% from the May 15th total of 992,100 shares. Based on an average trading volume of 467,200 shares, the short-interest ratio is currently 2.7 days. Approximately 2.3% of the company's stock are short sold.

InflaRx Stock Down 0.4%

Shares of IFRX traded down $0.00 during trading on Friday, reaching $0.80. The company's stock had a trading volume of 173,944 shares, compared to its average volume of 287,821. The company has a fifty day moving average of $1.26 and a two-hundred day moving average of $1.69. InflaRx has a twelve month low of $0.71 and a twelve month high of $2.82. The company has a market cap of $53.38 million, a price-to-earnings ratio of -0.97 and a beta of 1.29.

InflaRx (NASDAQ:IFRX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. InflaRx had a negative return on equity of 64.17% and a negative net margin of 33,362.70%. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. As a group, equities analysts forecast that InflaRx will post -1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On InflaRx

Several institutional investors and hedge funds have recently made changes to their positions in IFRX. Two Sigma Securities LLC acquired a new stake in shares of InflaRx during the 4th quarter valued at approximately $28,000. Cubist Systematic Strategies LLC raised its position in shares of InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock valued at $31,000 after acquiring an additional 7,616 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of InflaRx during the 1st quarter valued at approximately $38,000. Walleye Capital LLC acquired a new stake in shares of InflaRx during the 4th quarter valued at approximately $51,000. Finally, Geode Capital Management LLC raised its position in shares of InflaRx by 32.8% during the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock valued at $119,000 after acquiring an additional 11,900 shares in the last quarter. 42.39% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Oppenheimer reduced their price target on InflaRx from $6.00 to $3.00 and set an "outperform" rating on the stock in a research report on Thursday, May 29th. Raymond James Financial lowered InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 price target on the stock. in a research report on Thursday, May 29th. Guggenheim boosted their price target on InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a research report on Wednesday, March 26th. HC Wainwright reissued a "buy" rating and set a $8.00 price target on shares of InflaRx in a research report on Friday, March 21st. Finally, Cantor Fitzgerald assumed coverage on InflaRx in a research report on Tuesday, April 29th. They set an "overweight" rating and a $10.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $6.60.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.